INSIDER
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 458m ago
HOUSE PTR57m ago
SEC 13F57m ago
ROBINHOOD CHAIN57m ago
SEC FORM 4/Open-market saleVerified data

Manning Meredith sold SLNO

Chief Commercial Officer · SOLENO THERAPEUTICS INC · Common Stock

Side
SELL
Value
$65K
Shares
2,100
Price
$31.04
Executed
Mar 27, 2026
Disclosed
Mar 31, 2026
Disclosure timeline4 days from execution to publication · legal deadline 2 business days
Mar 27 executedMar 31, 2026 disclosed

SLNO · daily

Yahoo Finance chart API
▲Execution▼Disclosure●Material company filing●Other disclosed buy●Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.

Insider Score

Experimental signal
29/ 100 · ROUTINE
Methodology →
  • Transaction type+12 / 20

    Open-market sale

  • Relative size+4 / 25

    $65K reported value · 3.1% of prior position

  • Filing timing0 / 15

    Disclosed 2 business days after execution (deadline: 2)

  • Historical behavior+8 / 15

    First recorded trade by this actor in this security

  • Frequency & clustering+5 / 15

    1 other actor traded the same direction within 14 days

  • Market events0 / 10

    No material company filing within 60 days after the trade

    • The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.

    Other disclosed activity · SLNO

    ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
    9
    JM
    Joshi ManherChief Development Officer
    SLNOSOLENO THERAPEUTICS INC
    Disposition to issuer
    		D—
    72.3K sh
    		May 18, 2026May 18, 2026
    traded May 18, 2026
    		+0dSEC FORM 4

    Evidence

    5
    HF
    Huang Michael F.Sr. VP of Clinical Development
    SLNOSOLENO THERAPEUTICS INC
    Disposition to issuer
    		D—
    13.8K sh
    		May 18, 2026May 18, 2026
    traded May 18, 2026
    		+0dSEC FORM 4

    Evidence

    5
    HF
    Huang Michael F.Sr. VP of Clinical Development
    SLNOSOLENO THERAPEUTICS INC
    Disposition to issuer
    		D—
    110.0K sh
    		May 18, 2026May 18, 2026
    traded May 18, 2026
    		+0dSEC FORM 4

    Evidence

    5
    HF
    Huang Michael F.Sr. VP of Clinical Development
    SLNOSOLENO THERAPEUTICS INC
    Disposition to issuer
    		D—
    11.9K sh
    		May 18, 2026May 18, 2026
    traded May 18, 2026
    		+0dSEC FORM 4

    Evidence

    5
    HF
    Huang Michael F.Sr. VP of Clinical Development
    SLNOSOLENO THERAPEUTICS INC
    Disposition to issuer
    		D—
    39.8K sh
    		May 18, 2026May 18, 2026
    traded May 18, 2026
    		+0dSEC FORM 4

    Evidence

    9
    JM
    Joshi ManherChief Development Officer
    SLNOSOLENO THERAPEUTICS INC
    Disposition to issuer
    		D—
    20.2K sh
    		May 18, 2026May 18, 2026
    traded May 18, 2026
    		+0dSEC FORM 4

    Evidence

    9
    JM
    Joshi ManherChief Development Officer
    SLNOSOLENO THERAPEUTICS INC
    Disposition to issuer
    		D—
    4,700 sh
    		May 18, 2026May 18, 2026
    traded May 18, 2026
    		+0dSEC FORM 4

    Evidence

    33
    MM
    Manning MeredithChief Commercial Officer
    SLNOSOLENO THERAPEUTICS INC
    Open-market sale
    		SELL$146K
    4,864 sh
    		Mar 27, 2026Mar 31, 2026
    traded Mar 27, 2026
    		+4dSEC FORM 4

    Evidence

    26
    MM
    Manning MeredithChief Commercial Officer
    SLNOSOLENO THERAPEUTICS INC
    Open-market sale
    		SELL$18K
    558 sh
    		Mar 27, 2026Mar 31, 2026
    traded Mar 27, 2026
    		+4dSEC FORM 4

    Evidence

    33
    HF
    Huang Michael F.Sr. VP of Clinical Development
    SLNOSOLENO THERAPEUTICS INC
    Open-market sale
    		SELL$128K
    4,256 sh
    		Mar 27, 2026Mar 31, 2026
    traded Mar 27, 2026
    		+4dSEC FORM 4

    Evidence

    29
    HF
    Huang Michael F.Sr. VP of Clinical Development
    SLNOSOLENO THERAPEUTICS INC
    Open-market sale
    		SELL$57K
    1,838 sh
    		Mar 27, 2026Mar 31, 2026
    traded Mar 27, 2026
    		+4dSEC FORM 4

    Evidence

    26
    HF
    Huang Michael F.Sr. VP of Clinical Development
    SLNOSOLENO THERAPEUTICS INC
    Open-market sale
    		SELL$15K
    488 sh
    		Mar 27, 2026Mar 31, 2026
    traded Mar 27, 2026
    		+4dSEC FORM 4

    Evidence

    17
    HF
    Huang Michael F.Sr. VP of Clinical Development
    SLNOSOLENO THERAPEUTICS INC
    Grant or award
    		A—
    10.4K sh
    		Jan 21, 2026Jan 23, 2026
    traded Jan 21, 2026
    		+2dSEC FORM 4

    Evidence

    17
    JM
    Joshi ManherChief Development Officer
    SLNOSOLENO THERAPEUTICS INC
    Grant or award
    		A—
    4,100 sh
    		Jan 21, 2026Jan 23, 2026
    traded Jan 21, 2026
    		+2dSEC FORM 4

    Evidence

    9
    JM
    Joshi ManherChief Development Officer
    SLNOSOLENO THERAPEUTICS INC
    Grant or award
    		A—
    4,700 sh
    		Jan 21, 2026Jan 23, 2026
    traded Jan 21, 2026
    		+2dSEC FORM 4

    Evidence

    9
    NK
    Norrett KevinChief Business Officer
    SLNOSOLENO THERAPEUTICS INC
    Grant or award
    		A—
    4,000 sh
    		Jan 21, 2026Jan 23, 2026
    traded Jan 21, 2026
    		+2dSEC FORM 4

    Evidence

    21
    HC
    Hirano Patricia CSEE REMARKS
    SLNOSOLENO THERAPEUTICS INC
    Grant or award
    		A—
    10.4K sh
    		Jan 21, 2026Jan 23, 2026
    traded Jan 21, 2026
    		+2dSEC FORM 4

    Evidence

    9
    HC
    Hirano Patricia CSEE REMARKS
    SLNOSOLENO THERAPEUTICS INC
    Grant or award
    		A—
    11.9K sh
    		Jan 21, 2026Jan 23, 2026
    traded Jan 21, 2026
    		+2dSEC FORM 4

    Evidence

    21
    MM
    Manning MeredithChief Commercial Officer
    SLNOSOLENO THERAPEUTICS INC
    Grant or award
    		A—
    28.6K sh
    		Jan 21, 2026Jan 23, 2026
    traded Jan 21, 2026
    		+2dSEC FORM 4

    Evidence

    9
    MM
    Manning MeredithChief Commercial Officer
    SLNOSOLENO THERAPEUTICS INC
    Grant or award
    		A—
    32.8K sh
    		Jan 21, 2026Jan 23, 2026
    traded Jan 21, 2026
    		+2dSEC FORM 4

    Evidence

    Evidence

    Verified data

    Read directly from the primary public document; every field below is as reported by the filer.

    Source

    Document
    SEC Form 4
    Publisher
    U.S. Securities and Exchange Commission (EDGAR)
    Document ID
    0001752631-26-000002
    Machine-readable
    Structured copy

    Timestamps

    Event (reported)
    Mar 27, 2026
    Published
    Mar 31, 2026
    Ingested by INSIDER
    Nov 5, 04:08 UTC
    Last re-read
    Nov 5, 04:08 UTC

    Extracted facts

    Filer
    Manning Meredith
    Role
    Chief Commercial Officer
    Transaction
    Open-market saleAs filed: “S”
    Asset
    SOLENO THERAPEUTICS INC
    Ticker
    SLNO
    Shares
    2,100
    Price per share
    $31.04
    Value
    $65,181
    Execution date (reported)
    Mar 27, 2026
    Owned after transaction
    65.1K shares
    Days from execution to publication
    4

    Calculation

    Value = shares × reported price per share

    • Shares: 2,100
    • Price: $31.0384

    = $65,181

    What this establishes

    Manning Meredith filed this Form 4 reporting a open-market sale of SLNO on Mar 27, 2026. It became public on Mar 31, 2026. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.

    Extraction

    Method
    Form 4 XML
    Confidence
    1.00
    Chief Commercial Officer
    Manning Meredithcik:0001752631
    Issuer
    SOLENO THERAPEUTICS INCcik:0001484565

    Revision history · 0

    No field has changed since this record was first ingested.

    Company events

    No records

    No material filings recorded for this issuer.

    Source error

    Price history for SLNO is unavailable.

    An error occurred in the Server Components render. The specific message is omitted in production builds to avoid leaking sensitive details. A digest property is included on this error instance which may provide additional details about the nature of the error.